View Older Stories View More Recent Stories

Mar 31, 2021 05:00PM Alnylam Pharma (ALNY) Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in NEJM
Mar 31, 2021 05:00PM Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine
Mar 29, 2021 08:00AM Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day
Mar 23, 2021 08:00AM Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
Mar 11, 2021 08:30AM Alnylam Issues Inaugural Corporate Responsibility Summary
Mar 9, 2021 08:00AM Soleo Health to Administer Alnylam Pharmaceuticals’ GIVLAARI® (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults
Feb 22, 2021 04:00PM Alnylam to Webcast Presentations at Upcoming March Investor Conferences
Feb 18, 2021 04:00PM Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Feb 11, 2021 08:00AM Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
Jan 28, 2021 08:00AM Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2020 Financial Results
Jan 10, 2021 01:00PM Alnylam Launches “Alnylam P⁵x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years
Jan 7, 2021 07:03AM Alnylam Pharma (ALNY) HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy met Primary and Both Secondary Endpoints
Jan 7, 2021 07:00AM Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Jan 4, 2021 04:00PM Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference
Dec 21, 2020 08:00AM Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders
Dec 15, 2020 07:00AM Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day
Dec 8, 2020 08:00AM Alnylam to Webcast Virtual R&D Day
Dec 7, 2020 07:30AM Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Company’s Approved Therapies
Dec 3, 2020 01:52PM PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
Dec 3, 2020 08:00AM Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
Nov 25, 2020 08:00AM Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference
Nov 24, 2020 07:07AM Alnylam Pharma (ALNY) Reports FDA Approval of OXLUMO (lumasiran)
Nov 24, 2020 07:04AM Alnylam Pharma (ALNY) Announces Innovative Value-Based Agreement Framework for OXLUMO to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing
Nov 24, 2020 07:01AM Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO™ (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing
Nov 24, 2020 07:00AM Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO™ (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in P
Nov 13, 2020 09:02AM Alnylam Pharma (ALNY) Announces Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT
Nov 13, 2020 09:00AM Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
Nov 5, 2020 08:00AM Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity
Nov 2, 2020 04:00PM Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Oct 30, 2020 07:00AM Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran)
Oct 22, 2020 04:00PM Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results
Oct 22, 2020 10:02AM Alnylam Pharma (ALNY) Reports Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1
Oct 22, 2020 10:00AM Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
Oct 13, 2020 04:01PM Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference
Sep 30, 2020 07:01AM Alnylam Pharma (ALNY) Announces Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran
Sep 30, 2020 07:00AM Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
Sep 28, 2020 04:00PM Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference
Sep 3, 2020 07:30AM Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable
Sep 2, 2020 08:00AM Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Aug 17, 2020 07:33AM Blackstone (BX) and Alnylam (ALNY) Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease
Aug 17, 2020 07:30AM Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease
Aug 6, 2020 08:00AM Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity
Aug 6, 2020 07:40AM Alnylam Pharma (ALNY) Announces Planned Transition of Barry Greene, President
Aug 6, 2020 07:30AM Alnylam Announces Planned Transition of Barry Greene, President
Aug 3, 2020 07:34AM Alnylam Pharma (ALNY) Submits CTA Application for ALN-HSD, Investigational RNAi Therapeutic for the Treatment of NASH
Aug 3, 2020 07:30AM Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Jul 23, 2020 08:00AM Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results
Jun 18, 2020 07:00AM Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series
Jun 17, 2020 04:00PM Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference
Jun 1, 2020 07:00AM Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress
View More Recent Stories View Older Stories